CDC allegedly cancels Emory's HIV self-testing program after not enough workers left to oversee it
A local HIV program has allegedly been canceled as a result of funding cuts, firings and layoffs that have recently hit the Centers for Disease Control and Prevention, according to a program lead.
On April 22, the federal health agency informed Emory University in Atlanta that its large HIV self-testing program, called Together TakeMeHome, was being canceled two years early.
Dr. Patrick Sullivan, the project's lead scientist and professor of epidemiology at Emory University's Rollins School of Public Health, said he was told the cancellation is because the CDC does not have enough staffers to oversee the program.
MORE: Multiple health agency websites on HIV, contraception taken down to comply with executive orders
"CDC notified us that they had let go of so many CDC staff earlier in this year that they could no longer provide the required federal oversight for the project," he told ABC News. "It's really a tough rationale to accept. It really feels negligent to have sent home the staff that were needed to manage a really successful program that was improving the health of Americans, that was extending life, that was saving money and to not keep the resources in place to manage that."
Funded by the CDC, Together TakeMeHome, launched in March 2023 with an aim to make HIV at-home test kits available to Americans.
The CDC currently recommends that Americans between ages 13 and 64 be tested for HIV at least once in their lifetime. Sullivan said there are many reasons that make testing difficult including people living in more rural areas where testing is limited, costs or people preferring to test at home.
Since the program started, Sullivan said the team has mailed out around 750,000 HIV tests to households across the U.S. The test sent to households is the OraQuick In-Home HIV Test, which is approved by the Food and Drug Administration and provides results within 20 minutes.
Sullivan said about a quarter of the people who ordered a test through Together TakeMeHome had never been tested for HIV.
"In the time that we've operated, nearly 7,000 Americans have used the kits to learn that they are living with HIV, and that allows them to get into treatment, to protect their own health and to reduce the risk that they would transmit HIV to others," Sullivan said.
The team estimates that diagnosing those 7,000 people with HIV has prevented about 500 new HIV infections.
"Nearly $200 million in treatment costs have been saved just because of those infections that were avoided as people living with HIV learn their status and change their behaviors and get treated for their own infections," Sullivan said. "We had a program put in place, developed collaboratively with CDC, that was really making a difference, really moving the needle on ending the HIV epidemic, really improving people's health, really getting people the opportunity to connect with medical services that will literally save their lives."
MORE: 'We're all ticking time bombs': Budget cuts gut 9/11 health protections as community braces for crisis
President Donald Trump launched a program in 2019 with a goal to end the HIV epidemic in the U.S. by 2030.
However, several federal grants related to HIV and AIDS research have been terminated at the National Institutes of Health since the start of Trump's second term. The administration is also reportedly considering a plan to eliminate the CDC's Division of HIV Prevention, sources told ABC News.
The White House did not return ABC News' request for comment about the alleged plans.
Sullivan worries that the loss of Emory's program, along with the cancellation of other HIV research, could reverse the progress the U.S. has made in fighting the HIV epidemic.
"Part of public health's goal is to reach communities where there's the greatest need for services that aren't being met. When you can do all those things and see a return on investment -- see a net savings of money while we're improving the health of people -- that's exactly the kind of program that you really want to keep going," he said.
The CDC did not immediately reply to ABC News' request for comment.
CDC allegedly cancels Emory's HIV self-testing program after not enough workers left to oversee it originally appeared on abcnews.go.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Doctors recommend MMR vaccine amid measles outbreaks
(WKBN) — The Centers for Disease Control recently issued a travel warning for Americans as measles cases continue to rise around the world. Doctors say kids who are not vaccinated are at higher risk for serious problems from measles. The MMR vaccine helps protect against measles, mumps and rubella and has been used for many years. Dr. Camille Sabella with the Cleveland Clinic is a pediatric infectious disease specialist. She says the first dose of the MMR vaccine is given when a child is about 12 months old, and the second dose is given between 4 and 6 years old. Sabella says measles is a very contagious illness that spreads through coughing and sneezing. 'Most cases of measles in this country, and most of the outbreaks that we've had, began with someone who was not fully vaccinated against measles traveling internationally where measles is incredibly common,' Sabella said. Sabella says if you've recently traveled and have a rash, high fever, cough, runny nose or red, watery eyes, you should see a doctor right away but make sure you call before you go because you could be contagious. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
"Maintaining Strong Bones Has Less To Do With Drinking Tons Of Milk": Experts Are Sharing What To Foods May Negatively Impact Your Bone Density
My grandmother has osteoporosis, along with 10 million other Americans diagnosed with the disease and 43 million others with low bone mass. Not wanting to follow in her hobbled footsteps, the rest of the women in the family are taking precautions, including consuming the recommended amount of calcium (more isn't necessarily better), adding weight-bearing exercises to our exercise regimens and attending regular doctor checkups. But according to orthopedic specialists, protecting and maintaining strong bones has less to do with drinking tons of milk (those Got Milk campaigns certainly had their intended effect) and more to do with avoiding foods and beverages that can impact our bone density. Folks concerned about osteoporosis often add calcium and vitamin D to their diets, but these supplements could hurt your bone health rather than help if not taken as needed. Dr. Liz Matzkin, associate professor at Brigham and Women's Hospital in the Department of Orthopedic Surgery in Boston, explained: 'Although calcium and Vitamin D is important to maintain bone health, exceeding the recommended doses per day can backfire and be harmful rather than beneficial. Calcium and vitamin D requirements are age dependent, so make sure you are aware of the optimal dose for you.' She advised that, for ages 50 and over, the recommendations are 1,000 milligrams per day of calcium and 800 to 1000 international units per day of vitamin D. Below, orthopedic surgeons and specialists share the foods they avoid to help lessen their risk of osteoporosis. Alcohol Related: This Picky Eater Showdown Will Be Tough For People Without Refined Palates We don't blame you if you're totally confused about whether alcohol is a healthy or unhealthy addition to your diet. Whether you've heard it's beneficial for heart health or are concerned about its effect on the liver, Matzkin cautions that sipping a few glasses of pinot or chugging lagers can negatively affect bone health. 'An increased consumption of alcohol can alter the body's ability to absorb important nutrients that are actually beneficial to bone health, such as calcium, vitamin D and magnesium,' she explained. While calcium and vitamin D often get the spotlight in this area, our sex hormones, like testosterone in men and estrogen in women, are also critical for ensuring strong bones. Angelina Waller, a physician assistant at Advanced Orthopedics in Denver, explained that alcohol 'slows the bone remodeling cycle and disrupts hormone levels.' If you do like to imbibe, Matzkin recommends no more than one alcoholic beverage per day (which is the maximum amount women should be drinking anyway, according to the Centers for Disease Control and Prevention). Older folks and those who are at risk of bone breakage should be especially cautious. 'Lastly, if you consume too much alcohol, there is a higher risk of falling and injuring or fracturing a bone,' Matzkin said. A 2018 study found a link between alcohol consumption and hip fractures. Caffeine Related: If Your Fruit And Vegetable Knowledge Is Actually Good, Prove It By Getting 22/27 Of These Questions Right While America runs on coffee, it doesn't fuel our bones. And not just coffee. Add energy drinks, soda, tea and supplements or any product with caffeine to the hit list. Just like alcohol, the idea isn't abstention but moderation. 'Caffeine has been shown to increase calcium loss and decrease calcium absorption, both of which negatively influence bone health,' Matzkin said. 'Consider decaffeinated coffee or tea options if you just need something to warm you up or, even better, a tall glass of water.' The Food and Drug Administration recommends no more than 400 milligrams of caffeine a day (about 4-5 cups of coffee), which is a good guideline to use for bone health too. The bone builder vitamin D is also affected by caffeine, which can interfere with absorption. 'Caffeine causes decreased calcium absorption and increased calcium loss in the urine,' Waller said. Soda, particularly cola, is also a culprit of bad bone health. A 2006 comparative study found that drinking cola (including diet versions!) was associated with significantly lower bone mineral density in women. The level of consumption is related to the problem: The more cola the women drank, the more significant its impact. 'Soda contains sugars and can also contain phosphoric acid and caffeine,' Matzkin said. 'All of which fail to have any health benefits and, if consumed in large quantities, will result in negative health consequences.' Wheat Bran It may come as a surprise that heart-healthy wheat bran can have a negative effect on bone health. 'Wheat bran has high levels of phytates, which can prevent calcium absorption,' Matzkin explained. Many people eat wheat bran because it's high in dietary fiber, which is essential for keeping you regular, decreasing heart disease and even preventing colon cancer, all important considerations for many Americans. Thankfully, if you're a consumer of oat bran (which is different from wheat bran), it doesn't have the same deleterious effects on bones as wheat bran, according to Matzkin, as it doesn't contain high levels of phytates. Phytates are a type of anti-nutrient naturally found in plants. Many of your favorite veggies and legumes (from kale and cabbage to beans and peanuts) contain compounds that reduce the absorption of other nutrients. Pseudoscience makes a big deal out of avoiding these compounds, but for the most part, there's no reason to avoid these otherwise-healthy foods. Beans, spinach and beets also contain anti-nutrients that can decrease calcium absorption, but soaking (in the case of dried beans) or cooking (for raw spinach and beets) lessens their impact, according to Waller. 'Beans and wheat bran contain phytates, and spinach and beets contain oxalates that decrease calcium absorption as they bind to the calcium,' she said. If you want to reduce the phytates in wheat bran, you can try soaking, sprouting or fermenting it. Since it has tons of other benefits, there's no need to completely remove it from your diet, just moderate your intake. 'As with almost all foods, moderation is key,' Matzkin said. 'No need to completely eliminate wheat bran from the diet, but understanding that it can affect [calcium] absorption should prompt supplementation with other [calcium]-rich foods.' Salt Whether your tastes run salty or sweet or salty-sweet, the white stuff is typically associated with high blood pressure rather than bone loss. But it really should be a consideration for bone health, especially for older and at-risk groups. 'Be aware of salt that can be hidden in meats, snacks and processed foods such as cold cuts,' Matzkin said. 'Consuming excessive amounts of salt (more than 2,300 milligrams per day) can lead to calcium loss from your bones.' According to a 2018 study by the Journal of the American College of Nutrition, increased sodium consumption significantly increased the risk of osteoporosis. To put that in perspective, 2,300 milligrams per day is equal to 1 teaspoon of table salt, according to the FDA. On average, Americans are eating 1.5 times that amount. This post originally appeared on HuffPost. Also in Food: I'm Not Calling You Uncultured, But If You Can't Pass This International Food Also in Food: People Are Sharing The "Unneccessary" Cooking Rules They Stopped Following Ages Ago Also in Food: If You Can't Name At Least 10 Of These Fruits, You've Got The Taste Buds Of A Toddler
Yahoo
5 hours ago
- Yahoo
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & SullivanWebsite: PR@ To view the source version of this press release, please visit Sign in to access your portfolio
